Selected Articles from This Issue

Highlights| June 03 2024 Selected Articles from This Issue Author & Article Information Online ISSN: 1557-3265 Print ISSN: 1078-0432 ©2024 American Association for Cancer Research2024American Association for Cancer Research Clin Cancer Res (2024) 30 (11): 2295. https://doi.org/10.1158/1078-0432.CCR-30-11-HI Views Icon Views Article contents Figures & tables Video Audio Supplementary Data Peer Review Share Icon Share Facebook Twitter LinkedIn Email Tools Icon Tools Get Permissions Cite Icon Cite Search Site Article Versions Icon Versions Version of Record June 3 2024 Citation Selected Articles from This Issue. Clin Cancer Res 1 June 2024; 30 (11): 2295. https://doi.org/10.1158/1078-0432.CCR-30-11-HI Download citation file: Ris (Zotero) Reference Manager EasyBib Bookends Mendeley Papers EndNote RefWorks BibTex toolbar search Search Dropdown Menu toolbar search search input Search input auto suggest Search Advanced Search Preclinical studies have shown that androgen receptor-mediated CDK4/6 activation potentiates cell proliferation and endocrine therapy resistance in prostate cancer models, and CDK4/6 inhibition leads to tumor growth inhibition. The CDK4/6 inhibitor abemaciclib has been shown to significantly increase endocrine therapy efficacy in metastatic breast cancer, suggesting its potential as a treatment for patients with metastatic castration-resistant prostate cancer (mCRPC). In the phase II CYCLONE 1 study, Agarwal and colleagues evaluate the clinical activity of abemaciclib in heavily pretreated patients with refractory mCRPC. The authors report an objective response rate of 6.8% and a disease control rate of 45.5%, with a median time to PSA progression of 6.5 months, a 2.7-month median radiographic progression-free survival (rPFS), a 6-month rPFS rate of 24.9%, and an 8.4-month overall survival. Abemaciclib was well tolerated, with no treatment-related grade 4 or 5 adverse events. Overall, abemaciclib showed initial clinical activity in this heavily pretreated patient... You do not currently have access to this content.